Universe Pharmaceuticals Inc.(UPC)Earnings, Financials & Key Ratios

UPC•NASDAQ

Price updated Jun 19, 2026

SectorHealthcare IndustrySpecialty & Generic Pharma Sub-IndustryTraditional Chinese medicine producers

AboutUniverse Pharmaceuticals INC, a pharmaceutical company, engages in the manufacture, marketing, distribution, and sale of traditional Chinese medicine derivative products in China. It offers products for the treatment of common chronic health conditions in the elderly for physical wellness and longevity; and cold and flu medications. The company also distributes and sells third-party producers, including biomedical drugs, medical instruments, traditional Chinese medicine pieces products, and dietary supplements. Its customers include pharmaceutical companies, hospitals, clinics, and drugstore chains. The company was incorporated in 2019 and is based in Ji'An, China. Universe Pharmaceuticals INC is a subsidiary of Sununion Holding Group Limited.Show more

Revenue$18M-22.4%
EBITDA-$2M+68.2%
Net Income-$4M+57.9%
EPS (Diluted)-1055.75+26.5%
Gross Margin35.28%+33.8%
EBITDA Margin-13.43%+59.0%
Operating Margin-16.33%+53.1%
Net Margin-20.56%+45.8%
ROE-7.23%+64.8%

UPC Key Insights

Universe Pharmaceuticals Inc. (UPC) fundamental analysis — strengths, weaknesses & financial health based on data analysis

✓Strengths

✓High quality earnings: Operating CF exceeds net income
✓Share count reduced 42.8% through buybacks
✓Trading at only 0.0x book value

✗Weaknesses

✗Negative free cash flow
✗Sales declining 10.3% over 5 years
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.

Get notified when UPC posts new earnings or crosses analyst targets

Free. No account needed. Unsubscribe any time.

UPC Price & Volume

Universe Pharmaceuticals Inc. (UPC) stock price & volume — 10-year historical chart

Loading chart...

UPC Growth Metrics

Universe Pharmaceuticals Inc. (UPC) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR

Revenue CAGR

10 Years-

5 Years-10.27%

3 Years-23.66%

TTM-43.57%

Profit CAGR

10 Years-

5 Years-

3 Years-

TTM16.78%

EPS CAGR

10 Years-

5 Years-

3 Years-

TTM5.34%

Return on Capital

10 Years29.81%

5 Years-2.29%

3 Years-10.74%

Last Year-5.62%

Company	Market Cap	Stock Price	P/E Ratio (TTM)	Revenue Growth 1Y	Net Margin	Return on Equity (ROE)	Debt / Equity
HCWBHCW Biologics Inc.Direct Competitor	2.27M	1.09	-0.10	-97.89%	-24.73%	-102.39%	2.46
XTLBXTL Biopharmaceuticals Ltd.Direct Competitor	279.46K	2.54	-0.26		-227.72%	-25.53%	0.03
NUVBNuvation Bio Inc.Direct Competitor	1.93B	5.56	-9.27	6.99%	-102.06%	-44.1%	0.03
CPRXCatalyst Pharmaceuticals, Inc.Product Competitor	3.84B	31.38	18.68	19.78%	37.08%	23.65%	0.00
TLPHTalphera, Inc.Product Competitor	46.23M	1.09	-3.21		-14253%	-92.98%	0.38
SIGASIGA Technologies, Inc.Product Competitor	309.85M	4.32	13.09	-31.8%	21.61%	10.62%	0.00
HROWHarrow Health, Inc.Product Competitor	1.6B	42.87	-306.21	36.41%	-5.57%	-33.92%	4.84
MCKMcKesson CorporationSupply Chain	90.23B	750.63	19.56	12.36%	1.18%

Compare UPC vs Peers

Universe Pharmaceuticals Inc. (UPC) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs HCWB

Most directly comparable listed peer for UPC.

Scale Benchmark

vs MCK

Larger-name benchmark to compare UPC against a more recognizable public peer.

Peer Set

Compare Top 5

vs HCWB, XTLB, NUVB, CPRX

UPC Income Statement

Universe Pharmaceuticals Inc. (UPC) annual income statement — 10-year revenue, gross profit & net income history

10Y historyFree accessUpdated daily

Metric	Sep'18	Sep'19	Sep'20	Sep'21	Sep'22	Sep'23	Sep'24	Sep'25
Sales/Revenue	28.51M	33.23M	30.7M	47.98M	40.14M	32.31M	23.02M	17.86M
Revenue Growth %	-	16.54%	-7.6%	56.27%	-16.34%	-19.52%	-28.74%	-22.44%
Cost of Goods Sold	15.11M	19.82M	16.61M	22.66M	18.25M	21.99M	16.95M	11.56M
COGS % of Revenue	52.97%	59.65%	54.1%	47.22%	45.47%	68.07%	73.63%	64.72%
Gross Profit	13.41M▲ 0%	13.41M▼ 0.0%	14.09M▲ 5.1%	25.33M▲ 79.7%	21.89M▼ 13.6%	10.32M▼ 52.9%	6.07M▼ 41.1%	6.3M▲ 3.8%
Gross Margin %	47.03%	40.35%	45.9%	52.78%	54.53%	31.93%	26.37%	35.28%
Gross Profit Growth %	-	-0.01%	5.12%	79.7%	-13.56%	-52.88%	-41.14%	3.78%
Operating Expenses	3.65M	3.36M	3.74M	11.74M	28.91M	13.84M	14.09M	9.22M
OpEx % of Revenue	12.8%	10.1%	12.19%	24.46%	72.02%	42.84%	61.2%	51.61%
Selling, General & Admin	2.39M	2.29M	2.8M	6.27M	21.3M	9M	10.44M	8M
SG&A % of Revenue	8.36%	6.9%	9.1%	13.07%	53.05%	27.86%	45.36%	44.81%
Research & Development	789.38K	618.44K	583.13K	5.47M	7.62M	4.86M	3.03M	671.76K
R&D % of Revenue	2.77%	1.86%	1.9%	11.39%	18.99%	15.04%	13.16%	3.76%
Other Operating Expenses	474.63K	445.77K	365.77K	0	-7.53K	-17.53K	616.27K	542.97K
Operating Income	9.66M▲ 0%	9.75M▲ 1.0%	10.25M▲ 5.1%	13.59M▲ 32.6%	-7.02M▼ 151.7%	-3.53M▲ 49.8%	-8.02M▼ 127.4%	-2.92M▲ 63.6%
Operating Margin %	33.87%	29.35%	33.39%	28.32%	-17.49%	-10.92%	-34.83%	-16.33%
Operating Income Growth %	-	1%	5.12%	32.56%	-151.65%	49.76%	-127.4%	63.64%
EBITDA	10.11M	10.17M	10.66M	14.04M	-6.49M	-3.02M	-7.53M	-2.4M
EBITDA Margin %	35.45%	30.61%	34.72%	29.25%	-16.16%	-9.34%	-32.72%	-13.43%
EBITDA Growth %	-	0.62%	4.82%	31.66%	-146.2%	53.47%	-149.64%	68.16%
D&A (Non-Cash Add-back)	452.73K	418.43K	410.08K	446.88K	533.95K	508.79K	485.73K	517.43K
EBIT	9.68M	9.78M	10.22M	13.78M	-6.93M	-3.69M	-7.84M	-3.44M
Net Interest Income	-164.92K	-129.27K	-123.76K	-101.6K	-162.4K	-156.79K	-278.17K	-232.04K
Interest Income	0	0	0	0	0	0	0	0
Interest Expense	164.92K	129.27K	123.76K	101.6K	162.4K	156.79K	278.17K	232.04K
Other Income/Expense	-138.28K	-99.77K	-151.29K	57.51K	-545.35K	-413.77K	-100.75K	-756.14K
Pretax Income	9.52M▲ 0%	9.65M▲ 1.4%	10.1M▲ 4.6%	13.65M▲ 35.1%	-7.98M▼ 158.5%	-3.94M▲ 50.6%	-8.12M▼ 106.1%	-3.67M▲ 54.8%
Pretax Margin %	33.38%	29.05%	32.9%	28.44%	-19.89%	-12.2%	-35.27%	-20.56%
Income Tax	1.92M	2.1M	2.54M	2.36M	752.42K	2.25M	606.7K	0
Effective Tax Rate %	20.12%	21.77%	25.17%	17.28%	-9.42%	-57.19%	-7.47%	0%
Net Income	7.6M▲ 0%	7.55M▼ 0.7%	7.56M▲ 0.1%	11.32M▲ 49.8%	-8.74M▼ 177.2%	-6.16M▲ 29.5%	-8.73M▼ 41.6%	-3.67M▲ 57.9%
Net Margin %	26.66%	22.73%	24.62%	23.59%	-21.76%	-19.08%	-37.9%	-20.56%
Net Income Growth %	-	-0.68%	0.09%	49.77%	-177.18%	29.46%	-41.61%	57.92%
Net Income (Continuing)	7.6M	7.55M	7.56M	11.29M	-8.74M	-6.19M	-8.73M	-3.67M
Discontinued Operations	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0
EPS (Diluted)	1303.36▲ 0%	1294.54▼ 0.7%	1295.70▲ 0.1%	2147.18▲ 65.7%	-1475.02▼ 168.7%	-1040.53▲ 29.5%	-1436.12▼ 38.0%	-1055.75▲ 26.5%
EPS Growth %	-	-0.68%	0.09%	65.72%	-168.7%	29.46%	-38.02%	26.49%
EPS (Basic)	1303.36	1294.54	1295.70	2147.18	-1475.02	-1040.53	-1436.12	-1055.75
Diluted Shares Outstanding	5.83K	5.83K	5.83K	5.27K	5.92K	5.92K	6.08K	3.48K
Basic Shares Outstanding	5.83K	5.83K	5.83K	5.27K	5.92K	5.92K	6.08K	3.48K
Dividend Payout Ratio	40.25%	211.95%	-	-	-	-	-	-

UPC Balance Sheet

Universe Pharmaceuticals Inc. (UPC) balance sheet — assets, liabilities & shareholders' equity

Metric	Sep'18	Sep'19	Sep'20	Sep'21	Sep'22	Sep'23	Sep'24	Sep'25
Total Current Assets	21.96M	12.23M	22.84M	50.48M	41.51M	36.81M	51.64M	53.6M
Cash & Short-Term Investments	6.19M	3.18M	10.06M	21.8M	18.86M	18.5M	29.5M	33.59M
Cash Only	6.19M	3.18M	10.06M	8.08M	5.71M	5.29M	29.5M	33.59M
Short-Term Investments	0	0	0	13.73M	13.15M	13.22M	0	0
Accounts Receivable	7.64M	6.42M	10.87M	15.81M	15.18M	10.73M	17.88M	13.19M
Days Sales Outstanding	97.76	70.53	129.24	120.27	138.06	121.21	283.4	269.5
Inventory	8.12M	2.62M	1.91M	2.46M	2.21M	3.34M	1.74M	2.19M
Days Inventory Outstanding	196.22	48.16	41.89	39.67	44.13	55.48	37.4	69.26
Other Current Assets	0	0	443.71K	174.05K	1.72M	626.24K	852.42K	39.94K
Total Non-Current Assets	6.12M	5.61M	5.52M	19.66M	18.03M	16.48M	16.32M	15.7M
Property, Plant & Equipment	5.08M	4.57M	4.43M	15.39M	13.58M	14.99M	15.34M	14.7M
Fixed Asset Turnover	5.62x	7.28x	6.93x	3.12x	2.96x	2.16x	1.50x	1.21x
Goodwill	0	0	0	0	0	0	0	0
Intangible Assets	183.58K	171.61K	174.78K	178.48K	157.45K	148.58K	262.88K	296.79K
Long-Term Investments	728K	700.5K	735K	744.92K	702.89K	685.31K	712.49K	702.35K
Other Non-Current Assets	0	0	0	2.48M	2.25M	0	0	0
Total Assets	28.08M▲ 0%	17.84M▼ 36.5%	28.8M▲ 61.5%	70.14M▲ 143.5%	59.54M▼ 15.1%	53.29M▼ 10.5%	67.95M▲ 27.5%	69.3M▲ 2.0%
Asset Turnover	1.02x	1.86x	1.07x	0.68x	0.67x	0.61x	0.34x	0.26x
Asset Growth %	-	-36.48%	61.49%	143.52%	-15.12%	-10.5%	27.52%	1.99%
Total Current Liabilities	18.4M	5.45M	8M	11.21M	13.1M	13.75M	20.31M	13.17M
Accounts Payable	2.94M	1.94M	2.69M	5.31M	3.08M	4.59M	4.91M	1.67M
Days Payables Outstanding	71	35.67	59.14	85.56	61.5	76.1	105.82	52.73
Short-Term Debt	2.62M	2.52M	2.65M	4.33M	3.94M	5.48M	5.86M	9.26M
Deferred Revenue (Current)	893.51K	0	0	0	0	0	0	40.71K
Other Current Liabilities	-893.51K	0	956.49K	0	3.38M	0	0	0
Current Ratio	1.19x	2.24x	2.85x	4.50x	3.17x	2.68x	2.54x	4.07x
Quick Ratio	0.75x	1.76x	2.62x	4.28x	3.00x	2.43x	2.46x	3.90x
Cash Conversion Cycle	222.98	83.02	111.99	74.39	120.68	100.6	214.98	286.03
Total Non-Current Liabilities	0	0	0	0	7.01M	0	2.14M	0
Long-Term Debt	0	0	0	0	0	0	2.14M	0
Capital Lease Obligations	0	0	0	0	0	0	0	0
Deferred Tax Liabilities	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	0	0	0	0	0	0	0	0
Total Liabilities	18.4M	5.45M	8M	11.21M	13.1M	13.75M	22.45M	13.17M
Total Debt	2.62M	2.52M	2.65M	4.33M	3.94M	5.48M	7.99M	9.26M
Net Debt	-3.57M	-655.52K	-7.41M	-3.74M	-1.78M	197.21K	-21.5M	-24.34M
Debt / Equity	0.27x	0.20x	0.13x	0.07x	0.08x	0.14x	0.18x	0.16x
Debt / EBITDA	0.26x	0.25x	0.25x	0.31x	-	-	-	-
Net Debt / EBITDA	-0.35x	-0.06x	-0.70x	-0.27x	-	-	-	-
Interest Coverage	58.71x	75.67x	82.61x	135.63x	-42.68x	-23.55x	-28.19x	-14.83x
Total Equity	9.68M▲ 0%	12.38M▲ 27.9%	20.8M▲ 68.0%	58.93M▲ 183.3%	46.44M▼ 21.2%	39.53M▼ 14.9%	45.5M▲ 15.1%	56.13M▲ 23.4%
Equity Growth %	-	27.91%	67.98%	183.3%	-21.2%	-14.88%	15.1%	23.35%
Book Value per Share	1659.79	2123.10	3566.42	11178.75	7841.01	6674.44	7487.73	16138.44
Total Shareholders' Equity	9.68M	12.38M	20.8M	58.93M	46.44M	39.53M	45.5M	56.13M
Common Stock	50K	50K	50K	67.97K	67.97K	67.97K	482.4K	6.34M
Retained Earnings	2.83M	6.18M	13.74M	25.06M	16.32M	10.16M	-10.17M	-13.84M
Treasury Stock	0	0	0	0	0	0	0	0
Accumulated OCI	3.12M	2.47M	3.33M	4.53M	772.83K	26.27K	1.33M	626.01K
Minority Interest	0	0	0	0	0	0	0	0

UPC Cash Flow Statement

Universe Pharmaceuticals Inc. (UPC) cash flow — operating, investing & free cash flow history

Metric	Sep'18	Sep'19	Sep'20	Sep'21	Sep'22	Sep'23	Sep'24	Sep'25
Cash from Operations	4.46M	13.2M	6.12M	-2.06M	-1.31M	1.12M	-9.51M	-5.05M
Operating CF Margin %	15.63%	39.74%	19.92%	-4.28%	-3.27%	3.47%	-41.29%	-28.29%
Operating CF Growth %	-	196.34%	-53.69%	-133.62%	36.17%	185.35%	-948.75%	46.86%
Net Income	7.6M	7.55M	7.56M	11.32M	-7.91M	-6.58M	-8.73M	-3.67M
Depreciation & Amortization	452.73K	418.43K	410.08K	446.88K	533.95K	508.79K	485.73K	517.43K
Stock-Based Compensation	0	0	0	0	0	0	0	0
Deferred Taxes	17.54K	-39.63K	-9.89K	-668.34K	-542.38K	1.57M	606.7K	0
Other Non-Cash Items	-85.19K	112.79K	22.71K	-468.17K	5.97K	-45.74K	186.19K	370.6K
Working Capital Changes	-3.53M	5.16M	-1.87M	-12.69M	6.6M	5.67M	-2.06M	-2.27M
Change in Receivables	-2.82M	665.49K	-4.11M	-3.87M	-1.55M	4.72M	-1.71M	3.13M
Change in Inventory	-327.26K	5.59M	888.61K	-451.63K	16.59K	-1.18M	1.64M	-474.63K
Change in Payables	265.17K	-924.44K	639.43K	2.46M	-1.9M	1.64M	143.75K	-3.13M
Cash from Investing	-145.09K	-86.03K	-51.8K	-27.06M	-3.91M	-44.17K	-361.29K	-341.81K
Capital Expenditures	-145.09K	-86.32K	-51.8K	-13.53M	-93.7K	-44.17K	-245.8K	-266.77K
CapEx % of Revenue	0.51%	0.26%	0.17%	28.2%	0.23%	0.14%	1.07%	1.49%
Acquisitions	0	291	0	26.62M	-3.81M	0	0	0
Investments	-	-	-	-	-	-	-	-
Other Investing	0	0	0	-26.62M	523	0	-115.49K	-75.04K
Cash from Financing	-4.91M	-16M	470.14K	26.58M	3.32M	-1.39M	33.95M	9.73M
Debt Issued (Net)	-1.85M	1.14K	911.2K	624.35K	3.32M	-1.39M	8.95M	-5.27M
Equity Issued (Net)	0	0	0	28.75M	0	0	25M	15M
Dividends Paid	-3.06M	-16M	0	0	0	0	0	0
Share Repurchases	0	0	0	0	0	0	0	0
Other Financing	0	0	-441.06K	-2.79M	0	0	0	0
Net Change in Cash	-793.24K▲ 0%	-3.01M▼ 279.8%	6.88M▲ 328.4%	-1.98M▼ 128.8%	-2.37M▼ 19.5%	-426.21K▲ 82.0%	24.21M▲ 5780.9%	4.09M▼ 83.1%
Free Cash Flow	4.31M▲ 0%	13.12M▲ 204.3%	6.06M▼ 53.8%	-15.59M▼ 357.1%	-1.41M▲ 91.0%	1.08M▲ 176.5%	-9.87M▼ 1017.3%	-5.4M▲ 45.3%
FCF Margin %	15.12%	39.48%	19.75%	-32.49%	-3.5%	3.33%	-42.87%	-30.23%
FCF Growth %	-	204.31%	-53.78%	-357.07%	90.98%	176.52%	-1017.34%	45.29%
FCF per Share	738.99	2248.83	1039.49	-2956.58	-237.39	181.65	-1624.12	-1552.47
FCF Conversion (FCF/Net Income)	0.59x	1.75x	0.81x	-0.18x	0.15x	-0.18x	1.09x	1.38x
Interest Paid	183.07K	135.72K	157.53K	149.3K	199.85K	190.18K	304.52K	289.38K
Taxes Paid	1.7M	2.26M	2.17M	3.27M	2.75M	863.8K	0	0

UPC Key Ratios

Universe Pharmaceuticals Inc. (UPC) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios

Metric	2018	2019	2020	2021	2022	2023	2024	2025
Return on Equity (ROE)	78.53%	68.45%	45.55%	28.39%	-16.58%	-14.34%	-20.53%	-7.23%
Return on Invested Capital (ROIC)	118.49%	82%	61.22%	29.72%	-10.54%	-6.27%	-18.88%	-7.84%
Gross Margin	47.03%	40.35%	45.9%	52.78%	54.53%	31.93%	26.37%	35.28%
Net Margin	26.66%	22.73%	24.62%	23.59%	-21.76%	-19.08%	-37.9%	-20.56%
Debt / Equity	0.27x	0.20x	0.13x	0.07x	0.08x	0.14x	0.18x	0.16x
Interest Coverage	58.71x	75.67x	82.61x	135.63x	-42.68x	-23.55x	-28.19x	-14.83x
FCF Conversion	0.59x	1.75x	0.81x	-0.18x	0.15x	-0.18x	1.09x	1.38x
Revenue Growth	-	16.54%	-7.6%	56.27%	-16.34%	-19.52%	-28.74%	-22.44%

UPC Frequently Asked Questions

Universe Pharmaceuticals Inc. (UPC) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials

Universe Pharmaceuticals Inc. (UPC) reported $40.9M in revenue for fiscal year 2025. This represents a 43% increase from $28.5M in 2018.

Universe Pharmaceuticals Inc. (UPC) saw revenue decline by 22.4% over the past year.

Universe Pharmaceuticals Inc. (UPC) reported a net loss of $12.4M for fiscal year 2025.

Dividend & Returns

Universe Pharmaceuticals Inc. (UPC) has a return on equity (ROE) of -7.2%. Negative ROE indicates the company is unprofitable.

Universe Pharmaceuticals Inc. (UPC) had negative free cash flow of $15.2M in fiscal year 2025, likely due to heavy capital investments.

What if you invested $1,000 in UPC back in 2018?

Total return calculator · dividends reinvested · 8+ years of data

See returns →

How much would $100/month in UPC be worth today?

Dollar cost averaging calculator · DCA vs lump sum

Calculate →

Universe Pharmaceuticals Inc.(UPC)Earnings, Financials & Key Ratios

UPC•NASDAQ

Price updated Jun 19, 2026

SectorHealthcare IndustrySpecialty & Generic Pharma Sub-IndustryTraditional Chinese medicine producers

Revenue$18M-22.4%
EBITDA-$2M+68.2%
Net Income-$4M+57.9%
EPS (Diluted)-1055.75+26.5%
Gross Margin35.28%+33.8%
EBITDA Margin-13.43%+59.0%
Operating Margin-16.33%+53.1%
Net Margin-20.56%+45.8%
ROE-7.23%+64.8%